ArticleCancer medicine2026
The Molecular and Immunological Landscape in Nasopharyngeal Carcinoma (NPC) Differs by Somatostatin Receptor 2 (SSTR2) Expression.
Article in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Somatostatin receptor 2 is expressed in nasopharyngeal carcinoma (NPC). We report genomic and transcriptomic analysis results of 163 NPC cases, demonstrating that somatostatin receptor 2 (SSTR2) gene expression in EBV-positive and in EBV-negative NPC correlated with genomic alterations and an inflamed microenvironment. Median SSTR2 expression was 6.52 transcripts per million (TPM), ranging from 0.59 TPM (Quartile 1 [Q1], 18.2% EBV-positive) to 35.79 TPM (Q4, 82.9% EBV-positive). PIK3CA (20.51%) and CYLD (10.53%)/NFKBIA (12.82%) mutations were enriched in SSTR2-Q1 versus -Q4. Tumor mutation burden was negatively correlated (R = -0.27, p < 0.001) with SSTR2, while PD-L1 tumor proportion score (2% vs. 92.5% [SSTR2:Q1 vs. Q4], p < 0.001) and T-cell inflamed score correlated with SSTR2 expression (R = 0.53, p < 0.001). B-cells, M1 macrophages, CD8+ T-cells, Treg cells, and dendritic cells were enriched in SSTR2-Q4, while neutrophils were prominent in SSTR2-Q1. These results demonstrate a significant positive correlation between SSTR2 expression and an inflamed tumor microenvironment in NPC. This suggests that SSTR2 expression in NPC may be a clinically useful biomarker, correlating with the tumor microenvironment (including, potentially, sensitivity to immunotherapy) and its genetic profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.